Alembic Pharma gets USFDA nod for Fenofibrate Capsules
Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia(Fredrickson Type IV and V hyperlipidemia).
Vadodara: Drugmaker, Alembic Pharmaceuticals Limited, has recently announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Tricor Micronized Capsules, 67 mg, 134 mg and 200 mg, of AbbVie Inc. (AbbVie).
Fenofibrate Capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipideniia (Fredrickson Types Ila and llb).
Lipidaltering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia).
Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg have an estimated market size of US$ 17 million for twelve months ending June 2020 according to IQVIA.
Alembic has a cumulative total of 133 ANDA approvals (115 final approvals and 18 tentative approvals) from USFDA.
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.